There are increasing concerns over the presence and implications of pharmaceutical agents in water. In 2002, California banned pharmaceutical use of lindane because of concerns about water quality, as lindane treatment for head lice and scabies was found to be a significant factor adversely affecting wastewater quality. OBJECTIVES: In this article we describe the effects the ban has had on wastewater quality, unintentional exposures, and clinical practice. This is the first time that a pharmaceutical has been outlawed to protect water quality. As such, this ban provides a rare opportunity to evaluate the possible or potential outcomes of future public health interventions aimed at reducing pharmaceutical water contamination.
Approximately 100 different human pharmaceuticals have been identified at low levels in wastewater treatment plant effluents, surface waters, seawaters, groundwater, and some drinking waters from around the world (Fent et al. 2006; Hemminger 2005; Kolpin et al. 2002) . Classes of drugs that have been detected include analgesics and anti-inflammatories, beta-blockers, lipid regulators, antiepileptics, anti-depressants, oral contraceptives, and antibiotics. Intentional flushing of medications down the toilet, rinsing topically applied medications off in the tub or sink, and excretion of medications in urine or feces are the entry points for most pharmaceuticals into wastewater treatment systems. The federal government and a number of states have discouraged disposal of drugs by flushing them down the toilet, but this does not prevent contamination by rinsing or excretion. Although there are no documented health consequences from these exposures, there are concerns about the impact of long-term low-level exposures to medications, especially those that are environmentally persistent, and those that may bioaccumulate in the food chain. Impacts on ecologic systems are also of concern, especially in light of discovery of intersex fish in major waterways in the United States and their association with exposure to endocrine disruptors (Chambers and Leiker 2006) . Advanced water treatment technologies can remove many contaminants; however, this technology is expensive and may not be affordable for many municipalities. As communities look for alternative ways to manage pharmaceuticals and persistent chemicals in wastewater, the California ban on lindane deserves scrutiny as a potential approach to improve wastewater quality and limit global contamination with persistent organic pollutants (POPs).
Lindane, the gamma isomer of hexachlorocyclohexane (γ-HCH), is an environmentally persistent organochlorine insecticide manufactured since the 1940s for both agricultural and pharmaceutical purposes. In agriculture, lindane has been used as an insecticide to treat seeds, crops, and lumber/timber, and to treat cattle and other farm animals for ectoparasites. As a prescription medication, lindane is used as a topical treatment for human infestations of head lice and scabies.
Throughout the world, recognition of lindane's toxicity and its environmental persistence has resulted in an overall decline in use. (FDA 2003c) . In some instances, lindane has caused seizures after one application given according to package directions (FDA 2003a (FDA , 2003b .
Lindane is the least effective common pharmaceutical treatment for head lice when compared in vitro with other chemical alternatives including pyrethroids, malathion, or synergized pyrethrins (Meinking et al. 2002) . Because of toxicity concerns, in 1995 the FDA advised that lindane be labeled as second line therapy, only to be used after other treatments have failed (FDA 2003c) . In 2003, the FDA issued a "black box" public health warning for lindane treatments, reemphasizing that lindane should only be used as second line therapy and recommending use with caution in anyone weighing < 110 lb, the elderly, and those with seizure disorders (FDA 2003c) . Despite the cancellation for agricultural use, demonstrated toxicity in humans, and low efficacy in treating pediculosis (Meinking et al. 2002) To examine lindane prescribing trends in California, Medi-Cal fee-for-service pharmacy paid claims data for lindane were compiled for the fiscal years 1997 -2002 (California Department of Health Services 2007 . Nationwide data on the total number of lindane prescriptions by calendar years 1997-2006 were also compiled (Verispan Inc. 2007) .
Survey. We developed a written survey to elicit information about characteristics of provider practices, provider awareness and perception of the California lindane ban, and current treatment preferences for head lice and 
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1 9 8 9 1 9 8 8 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 (Figure 3) . Nationwide prescriptions for lindane during the same period declined similarly. In January 2002 California sales ended abruptly, coinciding with the ban. In contrast, since 2002 the rate of decline in national sales has slowed, as illustrated in Figure 3 .
Surveys. Of the 400 mailed surveys, 171 (43%) were returned after three mailings. No information was available for the nonresponders. Thirty-two surveys from nonpracticing physicians were excluded from the final analysis. In addition, 4 incomplete surveys were dropped from the group. The analysis was performed on the remaining 135 responses.
Responder characteristics. Table 1 describes the practice characteristics of the respondents. The majority (77%) of responding health providers practiced > 30 hr/week. Over one-half (55%) of the pediatricians practiced in a group private practice, 14% were in a health maintenance organization setting, and 13% of respondents were in solo practice. Approximately one-half (53%) of respondents were in practice for < 15 years.
Pediatricians differed substantially in the number of cases of head lice and scabies they typically manage in their practice. For head lice, 70 respondents (52%) reported managing 3-14 cases in the last 3 months, and 60 respondents (45%) managed < 2 cases; only 3% of the providers managed > 15 cases of head lice in the last 3 months. Similarly, for scabies, 50 pediatricians (37%) managed between 3 and 14 cases of in the last 3 months, and 79 (59%) managed ≤ 2 cases; only 4% managed > 15 cases of scabies in the last 3 months.
Response to lindane ban. More than onehalf (61%) of pediatricians reported using lindane before the ban, and the vast majority (81%) were aware of the ban. Of the providers who reported using lindane prior to the ban, virtually all (94%) reported changing their prescribing practices as a result of the ban.
Most respondents (78%) did not notice any difficulties after the lindane ban. However, 30 providers did report difficulties after the ban. Of these, most used lindane before the ban (26 of 30; 87%) and only 4 of 30 did not report prior lindane use. Those providers who reported that they had used lindane pre-ban and noticed difficulties after the ban were far more likely to be in solo private practice (35% vs. 7%) and to have been in practice > 15 years (58% vs. 44%). Providers reporting difficulty after the ban cited resistant lice as the main reason (97%); however, overall reports of resistant scabies were minimal (5%), as were increased cases of lice (7%) or scabies (1%). There were no significant differences among volume of head lice or scabies cases seen in the previous 3 months between providers who reported difficulties and those who did not.
Treatment preferences. The majority of respondents (69%) stated their first-line treatment preference for head lice was 1% permethrin, followed by 5% permethrin (9%) and other over-the-counter (OTC) methods including pyrethrum (8%). Respondent preference for second-line head lice treatment was malathion (51%), followed by 5% permethrin (19%). For scabies treatment, the majority (92%) of respondents expressed preference for 5% permethrin (92%), followed by crotamiton (5%). Second-line treatment preference for scabies included crotamiton (32%), followed by 5% permethrin (25%), malathion (21%), and others (22%).
Discussion
Wastewater concentrations. Because there was little to no agricultural use of lindane in urban areas of California, elevated wastewater concentrations of lindane were attributed to pharmaceutical lindane usage (CSDLAC 2001).
As Figure 1 illustrates, average concentrations of lindane were declining after 1991, paralleling reductions in prescriptions filled in California by Medi-Cal (Figure 3) 2,000,000 Unintentional ingestion and prescribing trends for lindane. Lice and scabies infestations are a worldwide problem, and are especially prevalent in institutions such as schools, prisons, and nursing homes. Infestations are usually not life-threatening, but they can be persistent and recurring, and they can cause considerable frustration and embarrassment in families. Whereas lindane was once an inexpensive and effective treatment, it is now more expensive than many alternatives (West 2004) and has been associated with widespread resistance throughout the world (Heukelbach and Feldmeier 2006; Ko and Elston 2004) .
A recent report shows that prescriptions for lindane in the Although there was a dramatic decline in lindane prescriptions filled under the Medi-Cal program in California in the 5 years prior to the ban, there were still > 11,000 filled in the year before the ban. Despite lindane's use as a second-line drug, unintentional ingestions from lindane were more likely to produce illness than ingestions of all alternative medications combined (pyrethrin/piperonyl butoxide, permethrin, and malathion) (CDC 2005b) . In contrast, calls related to lindane exposure to the California Poison Control System declined gradually from 1998 to 2002, but went to near zero after the ban. This information highlights the fact that, although the pharmaceutical use of lindane in states other than California has declined, there is still a significant volume of use and continued morbidity from unintentional exposures.
Summary of survey results. Three years after pharmaceutical use of the pesticide lindane was banned in California, our survey of practicing California pediatricians indicated that > 80% of physician respondents were aware of the ban, and a similar majority reported no difficulties complying with the ban. Despite outreach efforts by the State Department of Health Services and county public health officials, nearly two-thirds of pediatricians were prescribing lindane at least occasionally before the ban and had to change their prescribing practices as a result of the ban. The minority of providers who were using lindane and noticed difficulties after the ban were more likely to be in solo practice and to have been in practice > 15 years, suggesting a subpopulation of pediatricians who may benefit from education about alternative treatments for head lice and scabies. There was concordance among providers for current first line treatments for head lice and scabies.
Most providers did not report an increase in resistance of lice or scabies following the ban on lindane. One limitation of our survey is that it was not sensitive enough to distinguish between an increase in resistance predating the ban from any additional resistance temporally associated with the ban or thought to be related to the ban. Most chemical treatments for pediculosis will result in resistance over time (Downs 2004) . Written comments on our survey from providers suggest that either there was no additional increase in resistance after the ban or that any increase was unrelated. For instance, written responses from providers included these comments: "there seems to be an inexplicable decrease in both infestations"; "I think resistance and ban of Kwell are entirely unrelated"; and "only seeing rare clinical challenges now." As well, the California Department of Public Health has not identified an impact of the ban on either head lice or scabies outbreaks (Husted S, personal communication) .
This study is, to our knowledge, the first evaluation of the clinical and environmental effects of the California lindane ban. The main limitation of our survey was a survey response < 50%, although this response rate is similar to that from other published studies using mailed surveys (Asch et al. 1997; McMahon et al. 2003) . There is no information about the nonresponders. This low response rate could introduce bias. For example, if providers who experienced problems were more likely to respond to the survey, this would have overestimated reported difficulties following the lindane ban.
Alternatives to lindane for head lice/scabies treatment. The current recommended first-line treatment for head lice is OTC 1% permethrin (Frankowski and Weiner 2002) . Pediatricians in the California survey generally seemed to be aware of this and adhere to the guidelines. A recent Cochrane Review (Dodd 2001) found no evidence that any one pediculocide, including malathion, permethrin, and synergized pyrethrins, was more effective than another, although only 4 of 71 randomized, placebocontrolled studies met the inclusion criteria. Oral ivermectin has also been used when topical treatments cannot be used or when all other therapies have failed, although it is currently not FDA approved for this use (The Medical Letter 2005) .
A complete review of alternatives for the treatment of head lice and scabies is beyond the scope of this article; however, several recent publications provide such a discussion (Jones and English 2003; Karthikeyan 2005; Meinking 2004; Walker and Johnstone 2000) . Several recent uncontrolled studies on nonchemical treatments for head lice-relying on suffocation and desiccation-also show promise (Goates et al. 2006; The Medical Letter 2005; Pearlman 2004 ). In another recent small single-blinded, randomized study comparing common pediculocides to wet combing (nit removal by using a finetoothed comb through wet hair), Hill et al. (2005) found wet combing to be effective. These methods are preferable because they are not toxic to humans or the environment and are not susceptible to the development of resistance.
Environmental concerns. Currently, lindane may only be sold in the United States for use as a second-line treatment for head lice and scabies. However, the continued use and production of lindane raises international environmental pollution concerns and ethical issues.
For every ton of lindane that is produced, approximately 9 tons of toxic waste by-products are generated (CEC 2006) . Lindane is the γ-isomer of HCH and is isolated from a mixture of eight isomers in technical-grade HCH (CEC 2006) . None of the other HCH isomers are used commercially, and several are significantly more toxic and persistent than lindane itself, creating a disposal problem that has been poorly managed in many countries. Lindane production and use has resulted in contamination of products significant to children, such as butter and milk (Pardio et al. 2003; Waliszewski et al. 2003 (Jensen and Slorach 1991; Konishi et al. 2001; Schade and Heinzow 1998) . Similarly, biomonitoring data from the United States found levels of lindane below the limits of detection, and lower than in people from many other countries (CDC 2005a) . The β-HCH isomers are still found in measurable concentrations in Americans and were higher in Mexican Americans (CDC 2005a) .
Over the past two decades, there has been a steady decline in the production and use of lindane. Worldwide production of lindane is estimated to have decreased from 38,000 tons/ year in 1986 to approximately 3,222 tons/year during 1990 -1995 (International POPs Elimination Network 2007 . More recent figures are not available. However, it has been estimated that between 2 and 4.8 million tons of HCH waste by-products are present worldwide (Vijgen 2006) . These waste products are highly persistent chlorinated compounds; thus, there is no easy and effective way to dispose of them or remediate sites of production, creating a costly and hazardous situation. Production of lindane has moved from industrialized to developing countries, which raises ethical issues because the manufacturing country becomes the dumping ground for the waste. Documentation about production is sparse. Because it is joining the European Union, Romania is slated to discontinue production at the end of 2007. The remaining lindane production sites are thought to be only India and China (CEC 2006; Schade and Heinzow 1998) .
Lindane is registered for use in 17 countries, has been completely banned in > 50 countries, and has restricted use in 33 countries (CEC 2006) . In recognition of the global pollution resulting from POPs such as lindane, there have been international efforts to regulate and eliminate these substances. Mexico, the United States, and Canada, for instance, have collaborated in the North American Regional Plan to eliminate or ban the use of lindane where warranted and reduce the risks from exposure to HCH isomers (CEC 2006) . In addition, Mexico has nominated lindane and other HCH isomers as candidates for the Stockholm Convention, a global treaty to protect human health and the environment from POPs.
In summary, there are safer and more effective treatment alternatives for head lice and scabies. The experience in California has resulted in ecologic benefits, including the virtual elimination of lindane from California wastewater, and in the reduction of unintentional exposure calls to the Poison Control System. Our survey results suggest that the ban on the pharmaceutical use of lindane has not posed a significant problem for clinicians. Use and wastewater contamination did decrease in California during the years before the ban, likely resulting from California public outreach efforts, the FDA advisories, recommendations in the medical literature, and the availability of alternatives. However, use continued; it was ultimately the legislative ban that was correlated with improvements in California wastewater quality, a decrease in unintentional exposure calls, and the cessation of clinician use of lindane. Given the recognition of lindane and other HCH isomers as toxic and persistent chemicals with health consequences, coupled with the ethical issues of manufacturing in developing countries for use elsewhere, the harms of use and production may outweigh any residual benefit from maintaining it as a second-line therapy.
